Comparison of finasteride versus spironolactone in the treatment of idiopathic hirsutism

被引:53
作者
Erenus, M
Yucelten, D
Durmusoglu, F
Gurbuz, O
机构
[1] MARMARA UNIV,SCH MED,DEPT OBSTET & GYNECOL,ISTANBUL,TURKEY
[2] MARMARA UNIV,SCH MED,DEPT DERMATOL,ISTANBUL,TURKEY
关键词
finasteride; spironolactone; idiopathic hirsutism;
D O I
10.1016/S0015-0282(97)00371-3
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To compare the efficacy of finasteride and spironolactone in the treatment of idiopathic hirsutism. Design: Prospective, randomized, single-blind study. Setting: A tertiary hirsutism clinic. Patient(s): Forty-women with idiopathic hirsutism were selected. Intervention(s): Patients were assigned randomly to receive either 5 mg of finasteride or 100 mg of spironolactone for 9 months. Main Outcome Measure(s): Hirsutism scores were measured according to the Ferriman-Gallwey scoring system, and side effects were monitored for 9 months of treatment. Blood samples were taken at each visit for assessment; of endocrine, biochemical, and hematologic parameters. Result(s): Hirsutism scores were decreased significantly in both groups at the end of 9 months. The mean percent change (+/-SD) in hirsutism scores in the finasteride and spironolactone groups was as follows: 5.91% +/- 7.18% and 20.60% +/- 12.59% at 3 months, 10.61% +/- 12.18% and 32.57% +/- 15.68% at 6 months, and 15.15% +/- 15.38% and 42.36% +/- 12.31% at 9 months, respectively. There was a significantly better response with spironolactone treatment at the end of 9 months. Eleven (55%) of 20 patients in the spironolactone group experienced side effects. However, none of them stopped treatment because of side effects. Conclusion(s): The present data suggest that both finasteride and spironolactone are effective in the treatment of idiopathic hirsutism. However, it appears that the spironolactone group responded significantly better. (C) 1997 by American Society for Reproductive Medicine.
引用
收藏
页码:1000 / 1003
页数:4
相关论文
共 22 条
[1]   Outcome of long-term treatment with the 5 alpha-reductase inhibitor finasteride in idiopathic hirsutism: Clinical and hormonal effects during a 1-year course of therapy and 1-year follow-up [J].
Castello, R ;
Negri, C ;
Tosi, F ;
Muggeo, M ;
Perrone, F ;
Moghetti, P .
FERTILITY AND STERILITY, 1996, 66 (05) :734-740
[2]   CLINICAL AND ENDOCRINE EFFECTS OF FINASTERIDE, A 5-ALPHA-REDUCTASE INHIBITOR, IN WOMEN WITH IDIOPATHIC HIRSUTISM [J].
CIOTTA, L ;
CIANCI, A ;
CALOGERO, AE ;
PALUMBO, MA ;
MARLETTA, E ;
SCIUTO, A ;
PALUMBO, G .
FERTILITY AND STERILITY, 1995, 64 (02) :299-306
[3]   TREATMENT OF HIRSUTISM WITH SPIRONOLACTONE [J].
CUMMING, DC ;
YANG, JC ;
REBAR, RW ;
YEN, SSC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1982, 247 (09) :1295-1298
[4]  
CUSAN L, 1994, FERTIL STERIL, V61, P281
[5]   TREATMENT OF HIRSUTISM WITH CYPROTERONE-ACETATE (AN ANTI-ANDROGEN) [J].
DEWHURST, CJ ;
UNDERHILL, R ;
GOLDMAN, S ;
MANSFIELD, M .
BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1977, 84 (02) :119-123
[6]   Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism [J].
Erenus, M ;
Yucelten, D ;
Gurbuz, O ;
Durmusoglu, F ;
Pekin, S .
FERTILITY AND STERILITY, 1996, 66 (02) :216-219
[7]  
ERENUS M, 1994, FERTIL STERIL, V61, P613
[8]   CLINICAL ASSESSMENT OF BODY HAIR GROWTH IN WOMEN [J].
FERRIMAN, D ;
GALLWEY, JD .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1961, 21 (11) :1440-+
[9]   EFFECTS OF FINASTERIDE, A 5-ALPHA-REDUCTASE INHIBITOR, ON CIRCULATING ANDROGENS AND GONADOTROPIN-SECRETION IN HIRSUTE WOMEN [J].
FRUZZETTI, F ;
DELORENZO, D ;
PARRINI, D ;
RICCI, C .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (03) :831-835
[10]   GENETIC AND PHARMACOLOGICAL EVIDENCE FOR MORE THAN ONE HUMAN STEROID 5-ALPHA-REDUCTASE [J].
JENKINS, EP ;
ANDERSSON, S ;
IMPERATOMCGINLEY, J ;
WILSON, JD ;
RUSSELL, DW .
JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (01) :293-300